HER2Bi- or EGFRBi-armed anti-CD19 CAR T cells displayed specific cytotoxicity toward multiple HER2+/EGFR+/CD19- tumor targets in long-term serial killing assays. The gene discussed is ERBB2; the disease is neoplasm.